Xenon Pharmaceuticals Inc (XENE)
39.84
-0.47
(-1.17%)
USD |
NASDAQ |
Apr 19, 16:00
39.87
+0.03
(+0.08%)
After-Hours: 20:00
Xenon Pharmaceuticals Enterprise Value: 2.367B for April 19, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 19, 2024 | 2.367B |
| April 18, 2024 | 2.403B |
| April 17, 2024 | 2.502B |
| April 16, 2024 | 2.492B |
| April 15, 2024 | 2.478B |
| April 12, 2024 | 2.477B |
| April 11, 2024 | 2.603B |
| April 10, 2024 | 2.563B |
| April 09, 2024 | 2.608B |
| April 08, 2024 | 2.577B |
| April 05, 2024 | 2.549B |
| April 04, 2024 | 2.546B |
| April 03, 2024 | 2.477B |
| April 02, 2024 | 2.490B |
| April 01, 2024 | 2.541B |
| March 28, 2024 | 2.609B |
| March 27, 2024 | 2.606B |
| March 26, 2024 | 2.580B |
| March 25, 2024 | 2.583B |
| March 22, 2024 | 2.681B |
| March 21, 2024 | 2.639B |
| March 20, 2024 | 2.665B |
| March 19, 2024 | 2.707B |
| March 18, 2024 | 2.597B |
| March 15, 2024 | 2.678B |
| Date | Value |
|---|---|
| March 14, 2024 | 2.656B |
| March 13, 2024 | 2.762B |
| March 12, 2024 | 2.700B |
| March 11, 2024 | 2.709B |
| March 08, 2024 | 2.850B |
| March 07, 2024 | 2.844B |
| March 06, 2024 | 2.829B |
| March 05, 2024 | 2.832B |
| March 04, 2024 | 2.828B |
| March 01, 2024 | 2.895B |
| February 29, 2024 | 2.922B |
| February 28, 2024 | 2.971B |
| February 27, 2024 | 3.106B |
| February 26, 2024 | 3.068B |
| February 23, 2024 | 3.090B |
| February 22, 2024 | 3.074B |
| February 21, 2024 | 3.042B |
| February 20, 2024 | 3.011B |
| February 16, 2024 | 3.048B |
| February 15, 2024 | 3.032B |
| February 14, 2024 | 3.017B |
| February 13, 2024 | 2.984B |
| February 12, 2024 | 3.082B |
| February 09, 2024 | 3.133B |
| February 08, 2024 | 2.993B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
135.64M
Minimum
Apr 22 2019
3.133B
Maximum
Feb 09 2024
1.008B
Average
869.89M
Median
Enterprise Value Benchmarks
| Acasti Pharma Inc | 1.862M |
| Aurinia Pharmaceuticals Inc | 371.15M |
| Edesa Biotech Inc | 9.847M |
| Lexaria Bioscience Corp | 23.18M |
| ESSA Pharma Inc | 156.04M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -44.74M |
| Total Expenses (Quarterly) | 53.70M |
| EPS Diluted (Quarterly) | -0.64 |
| Earnings Yield | -6.83% |
| Normalized Earnings Yield | -4.565 |